Evaluation of the effectiveness of personalised therapy for the patients with irritable bowel syndrome.

Intestinal microbiota correction in the therapy of irritable bowel syndrome (IBS) is an important medical problem. We conducted a laboratory and pilot clinical trial to investigate the effect of autoprobiotic bacteria, indigenous bifidobacteria and enterococci isolated from faeces and grown on artificial media to use as personified food additives in IBS treatment. Convincing evidence of the clinical efficacy of autoprobiotic was demonstrated by the disappearance of dyspeptic symptoms.

Gastrointestinal microbiome and : Eradicate, leave it as it is, or take a personalized benefit-risk approach?

() is generally regarded as a human pathogen and a class 1 carcinogen, etiologically related to gastric and duodenal ulcers, gastric cancer, and mucosa-associated lymphoid tissue lymphoma. However, can also be regarded as a commensal symbiont. Unlike other pathogenic/ opportunistic bacteria, colonization in infancy is facilitated by T helper type 2 immunity and leads to the development of immune tolerance.

CE with Cu ions and 2-hydroxypropyl-β-cyclodextrin additives for the investigation of amino acids composition of the culture medium in a cellular model of non-alcoholic fatty liver disease.

CE method with CuSO and 2-hydroxypropyl-β-cyclodextrin additives in sodium acetate background electrolyte pH 4.3 for the simultaneous determination of amino acids and lactic acid was adapted for the comparative study of metabolism in "healthy" and non-alcoholic fatty liver disease model cells HepG2. In vitro model of the disease was developed by exposure HepG2 cells with oleate and palmitate to simulate an excessive flow of fatty acids into hepatocytes.

Acceptive Immunity: The Role of Fucosylated Glycans in Human Host-Microbiome Interactions.

The growth in the number of chronic non-communicable diseases in the second half of the past century and in the first two decades of the new century is largely due to the disruption of the relationship between the human body and its symbiotic microbiota, and not pathogens. The interaction of the human immune system with symbionts is not accompanied by inflammation, but is a physiological norm. This is achieved via microbiota control by the immune system through a complex balance of pro-inflammatory and suppressive responses, and only a disturbance of this balance can trigger pathophysiological mechanisms.